Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Calidi Biotherapeutics, Inc. Common Stock
(NY:
CLDI
)
1.320
-0.010 (-0.75%)
Streaming Delayed Price
Updated: 10:11 AM EST, Dec 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Calidi Biotherapeutics, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
April 18, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors
April 17, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
April 02, 2025
Via
Investor Brand Network
Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy
April 01, 2025
Via
Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
April 01, 2025
Via
Investor Brand Network
Natural Killer Cells That are Genetically Modified Show Potential in Cancer Immunotherapy
March 31, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
March 28, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
March 26, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
March 21, 2025
Via
Investor Brand Network
New Study Shows ‘Viral Mimicry’ Could Transform Glioblastoma Treatment
March 21, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers
March 14, 2025
Via
Investor Brand Network
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
March 14, 2025
Via
ACCESS Newswire
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
March 10, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies
March 05, 2025
Via
Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform
March 05, 2025
Via
Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show
February 28, 2025
Via
Investor Brand Network
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
February 28, 2025
Via
ACCESS Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research
February 25, 2025
Via
Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment
February 24, 2025
Via
Investor Brand Network
Topics
Death
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern
February 24, 2025
Via
Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors
February 21, 2025
Via
Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns
February 20, 2025
Via
Investor Brand Network
Which stocks are moving after the closing bell on Wednesday?
↗
February 19, 2025
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
These stocks are moving in today's after hours session
↗
February 05, 2025
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar on Feb. 5
January 29, 2025
Via
Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Ends SEPA Agreement Following Successful Fundraising
January 28, 2025
Via
Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025
January 14, 2025
Via
Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering
January 13, 2025
Via
Investor Brand Network
Topics
Regulatory Compliance
Why Calidi Biotherapeutics (CLDI) Stock Is Down 30%
↗
January 10, 2025
Calidi Biotherapeutics shares are trading lower by 32% during Friday's session. The company priced its public offering of 5 million shares of common stock at $0.85 per share.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 10, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today